See more : Digital Locations, Inc. (DLOC) Income Statement Analysis – Financial Results
Complete financial analysis of Suven Pharmaceuticals Limited (SUVENPHAR.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Suven Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Colgate-Palmolive Company (0P59.L) Income Statement Analysis – Financial Results
- Mirvac Group (MRVGF) Income Statement Analysis – Financial Results
- Quantum Capital Inc. (QTCI) Income Statement Analysis – Financial Results
- Tecan Group AG (TECN.SW) Income Statement Analysis – Financial Results
- Timah Resources Limited (TML.AX) Income Statement Analysis – Financial Results
Suven Pharmaceuticals Limited (SUVENPHAR.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.suvenpharm.com
About Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 10.51B | 13.40B | 12.90B | 9.80B | 8.07B | 3.66B |
| Cost of Revenue | 4.50B | 5.85B | 5.55B | 4.20B | 3.25B | 1.51B |
| Gross Profit | 6.01B | 7.55B | 7.35B | 5.60B | 4.82B | 2.15B |
| Gross Profit Ratio | 57.17% | 56.32% | 56.96% | 57.12% | 59.77% | 58.72% |
| Research & Development | 0.00 | 85.86M | 103.55M | 110.58M | 141.32M | 0.00 |
| General & Administrative | 1.37B | 188.97M | 170.64M | 160.52M | 137.51M | 68.23M |
| Selling & Marketing | 34.78M | 176.36M | 198.03M | 105.25M | 126.84M | 67.15M |
| SG&A | 1.40B | 1.11B | 368.67M | 265.77M | 264.35M | 135.38M |
| Other Expenses | 0.00 | 463.64M | 14.71M | 10.49M | 2.59M | 390.24M |
| Operating Expenses | 1.40B | 2.36B | 1.92B | 1.48B | 1.21B | 520.88M |
| Cost & Expenses | 5.91B | 8.22B | 7.47B | 5.69B | 4.46B | 2.03B |
| Interest Income | 20.15M | 58.32M | 686.00K | 2.68M | 3.61M | 1.98M |
| Interest Expense | 74.51M | 54.36M | 62.36M | 91.44M | 199.15M | 17.18M |
| Depreciation & Amortization | 545.96M | 477.32M | 390.97M | 316.36M | 235.07M | 114.97M |
| EBITDA | 4.68B | 6.20B | 6.74B | 4.57B | 4.00B | 1.72B |
| EBITDA Ratio | 44.49% | 45.73% | 49.52% | 51.54% | 54.77% | 46.67% |
| Operating Income | 4.61B | 5.19B | 5.42B | 4.10B | 3.58B | 3.91B |
| Operating Income Ratio | 43.83% | 38.71% | 41.99% | 41.83% | 44.41% | 106.64% |
| Total Other Income/Expenses | -550.93M | -706.22M | 342.03M | -153.90M | -114.42M | -51.16M |
| Income Before Tax | 4.06B | 5.60B | 6.68B | 4.68B | 4.05B | 1.58B |
| Income Before Tax Ratio | 38.59% | 41.76% | 51.76% | 47.72% | 50.13% | 43.10% |
| Income Tax Expense | 1.05B | 1.48B | 2.14B | 1.05B | 875.10M | 485.93M |
| Net Income | 3.00B | 4.11B | 4.54B | 3.62B | 3.17B | 1.09B |
| Net Income Ratio | 28.56% | 30.69% | 35.18% | 36.98% | 39.28% | 29.84% |
| EPS | 11.80 | 16.16 | 17.83 | 14.23 | 6.23 | 4.29 |
| EPS Diluted | 11.80 | 16.16 | 17.83 | 14.23 | 6.23 | 4.29 |
| Weighted Avg Shares Out | 254.48M | 254.57M | 254.56M | 254.57M | 509.13M | 254.56M |
| Weighted Avg Shares Out (Dil) | 254.56M | 254.57M | 254.56M | 254.57M | 509.13M | 254.56M |
Source: https://incomestatements.info
Category: Stock Reports